



# **Urine-ID Case Review**

# • Patient History:

45-year-old female patient with recurring UTI, previously treated with doxycycline.

### • Disease State:

Symptoms resolved for 3 weeks. Then burning and frequency of urinating returned. Initial C&S showed E. coli

• Why This Test was Ordered: The patient was having a severe recurring UTI that was not being resolved by a C&S.


### Outcome:

Vikor report showed no presence of E. coli, but 3 bacterial pathogens over 10<sup>6</sup> and 2 more mildly pathogenic bacteria with resistance to 4 antibiotics. In addition, patient showed 1-<sup>3</sup> count of BVB2 which was mildly pathogenic. Patient was prescribed Macrobid and Flagyl (following Vikor's treatment guidance) and symptoms resolved within a few days.

This treatment was just given last week, but the patient was quickly feeling relief after several visits to her PC and then GYN. Client was impressed to see how detailed Vikor's testing was and was finally able to address this patient's symptoms.

CONFIDENTIALITY NOTICE TO RECIPIENT: This transmission contains confidential information belonging to the sender that is legally privileged and proprietary and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIP AA). If you are not the intended recipient of this email, you are prohibited from sharing, copying, or otherwise using or disclosing its contents. If you have received this email in error, please notify the sender immediately by reply e-mail and permanently delete this email and any attachments without reading, forwarding, or saving them. Thank you.







www.vikorscientific.com

512 E. Township Line Rd; Ste #135 (Tower 4) Blue Bell, PA 19422 P: 854.429.1069 • F: 833.247.4091



#39D2166771

### Patient Name

**Facility Phone:** 







**UNDISCLOSED** 

**Facility Information** Specimen Information

ACC: Ordering Provider:

Facility:

Facility Fax:

Collection Date: 07-01-2021 Report Date: 07-03-2021 Received Date: 07-02-2021 Sample Type: Urine Swab

Notes:

# **Laboratory Results**

PATHOGENS DETECTED			
Klebsiella oxytoca	1 x 10^6 copies/uL	33.188%	
Klebsiella pneumoniae	1 x 10^6 copies/uL	33.188%	
Enterobacter cloacae	1 x 10^6 copies/uL	33.188%	
Enterococcus faecalis	1 x 10 <sup>4</sup> copies/uL	0.332%	
Streptococcus agalactiae	1 x 10 <sup>3</sup> copies/uL	0.033%	
Uncultured Megasphera 1	1 x 10 <sup>3</sup> copies/uL	0.033%	
BVAB2	1 x 10 <sup>3</sup> copies/uL	0.033%	
Mobiluncus curtisii and Mulieris	1 x 10 <sup>2</sup> copies/uL	0.003%	

# **RESISTANCE GENES DETECTED &** POTENTIAL MED CLASS AFFECTED

ermB	Macrolides	
tetM	Tetracycline	
ampC, ACC, DHA, ACT/MIR	Ampicillin	
BlaSHV	Beta-lactams	

ABXAssist<sup>™</sup>

# **Pharmacy Guidance Provided by:**




Electronically approved on 07-03-2021 by: Thamar Momo •Email: pharmconsult@vikorscientific.com • Phone: 1-855-742-7635, 1-855-PharmD5

Report Date: 07-03-2021 Printed: 07-03-2021 03:26

Ref:







512 E. Township Line Rd; Ste #135 (Tower 4) Blue Bell, PA 19422 P: 854.429.1069 • F: 833.247.4091 www.vikorscientific.com

Notes from Pharmacist:



### Patient Name



### Date of Birth



Gender



Race

UNDISCLOSED

Drug Allergies:	NONE	
Notes from Ordering Physician:	URINE	
	DISCLAIMERS:  1. The treatment guidance listed is based on infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information	

treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided. The provider should take the entire clinical presentation into account when making treatment decisions. Not all detected microbes will require antimicrobial therapy as some are part of the normal flora or can be non-pathogenic colonizers.

Treatment options take into account individual pathogens and potential resistances detected.

### RECURRENT UTI:

If UTI is recurrent (at least 2 UTIs in 6months or at least 3 UTIs in a year), consider combination therapy with Ceftriaxone 1G x1dose PLUS Bactrim DS or Cephalexin 500mg or Nitrofurantoin 100mg once daily at bedtime for 30 days. Be cautious of allergies.

Causative agents of Bacterial vaginosis (BV):BVAB2, Uncultured Megasphaera 1, Mobiluncus curtisii and mulieris. These are anaerobic organisms. Treat if symptomatic including symptomatic in pregnancy.

Clinician discretion whether to treat BV at low loads/percentages (Metronidazole (FLAGYL) 500mg BID x 7 days ( ok in pregnancy lower dose to 250mg q8h x7 days))

Enterococcus sp. is a part of the normal microflora, but when present at elevated levels it can be pathogenic. Treatment is recommended in symptomatic patients. Bactrim and cephalosporins are not effective. Recommended treatments are Augmentin, Nitrofurantoin (UTI), Doxycycline, Fosfomycin(UTI), Quinolones, and Linezolid. Be cautious of allergies.

	Medication	Route	Dose
FIRST LINE	sulfamethoxazole / trimethoprim	oral	Sulfamethoxazole/trimethoprim (BACTRIM) Double Strength: BID orally x 3-7 days for uncomplicated cystitis. BID orally x 7- 14 days for complicated cystitis.

Considerations: Covers Klebsiella, Enterobacter. 50% dose adjustment for CrCl < 30ml/min. Contraindicated CrCl < 15ml/min. Avoid use in Asthma pts and pregnancy. Avoid use with Warfarin. Avoid in pts with folate deficiency. Avoid pts with sulfa allergies. Longer duration in male patients.

......

MEDICATION REVIEW

Ref:





# Molecular Pathogen Report

512 E. Township Line Rd; Ste #135 (Tower 4) Blue Bell, PA 19422 P: 854.429.1069 • F: 833.247.4091 www.vikorscientific.com



#39D2166771

Race

**Patient Name** 

Date of Birth





**UNDISCLOSED** 

**SECOND LINE** 

nitrofurantoin

oral

Nitrofurantoin (MACROBID) 100mg orally BID x 5-7 days

Considerations: Covers Klebsiella, Enterobacter. Taking with food can reduce nausea/vomiting and increases bioavailability. Not effective in Pyelonephritis. Use caution and adjust dose CrCl < 60ml/min. Contraindicated CrCl < 30ml/min. Pregnancy category B. Contraindicated at 38-42 weeks term. Avoid G6PD. May cause brown or rust-yellow discoloration of urine.

ALTERNATIVE

ciprofloxacin

oral

Ciprofloxacin (CIPRO) 250 mg-500mg orally BID x 3-7 days for uncomplicated cystitis. 500mg orally BID x 7-14 days for complicated pyelonephritis. OR 400mg IV BID x 7 days for more serious infections.

Considerations: Covers Klebsiella, Enterobacter. Fluoroquinolones have been associated with serious and possible irreversible reactions: tendonitis/tendon rupture, peripheral neuropathy, CNS effects. These may occur all together or months after therapy. Increased risk in patients over 60 and patients on corticosteroids. Avoid in Myasthenia Gravis. Reserve for patients with no alternative therapy options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or uncomplicated UTI. Adjust dose for CrCl <50ml/min.

OR

fosfomycin

oral

Fosfomycin (MONUROL) 3G PO single dose. For uncomplicated cystitis only.

Considerations: Covers Klebsiella, Enterobacter. Do not use in pyelonephritis Caution in renal impairment. May require Prior Auth.

Methodology

The infectious disease and antibiotic resistance detection panels are tested utilizing Real-time PCR technology to detect the presence of genes associated with pathogens and antibiotic resistance via amplification of genomic DNA. Amplification and detection are performed using the Applied Biosystems™ QuantStudio™ 12K Flex Real-time PCR system, which includes the QuantStudio™ 12k Software v1.3 and Thermo Fisher Scientific TaqMan™ assays. The assays are preloaded onto TaqMan™ OpenArray plates.

Limitations

This test only detects microorganisms and antibiotic resistance (ABR) genes specified in the panel. ABR genes are detected in the specimen and are not specific to a detected pathogen. ABR genes may be detected in bacterial strains not tested for in the panel.

Disclaime


The resistance genes for Ampicillin, selected Extended-Spectrum-Betalactamases, Vancomycin, Carbapenems, Sulfonamide, Trimethoprim, Aminoglycosides and the Quinolone gyrase groupings are assays customized by pooling the individual genes listed in the associated group. If listed as positive, this indicates that at least one of the genes in the group was detected and the class of medication could have potential resistance.

This test was developed and its performance characteristics determined by KorGene™. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. Pharmacy guidance and recommendations therein are not under the purview of the laboratory or agencies which accredit the laboratory.

The treatment guidance listed in the report is based on infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the patient information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided. KorGene™ is currently in the Accreditation phase by the College of American Pathologist (CAP).

Report Date: 07-03-2021 Printed: 07-03-2021 03:26







512 E. Township Line Rd; Ste #135 (Tower 4) Blue Bell, PA 19422 P: 854.429.1069 • F: 833.247.4091 www.vikorscientific.com



#### Patient Name



#### ate of Birth



Gender



UNDISCLOSED
UNDISCLOSE

NEGATIVE PATHOGENS		
Acinetobacter baumannii	aac	:6-1b
Actinobaculum schaali	SU	LL, [
Aerococcus urinae	CT	X-M,
Alloscardovia Omnicolens	OX	A-23
Atopobium vaginae	blac	OXA
Candida albicans	erm	ıC, ε
Candida glabrata	me	cA
Candida krusei	mcı	r-1
Candida parapsilosis		S_P
Candida tropicalis		3L_T
Chlamydia trachomatis	var	nB, \
Citrobacter freundii		
Citrobacter koseri		
Corynebacterium riegelii		
Corynebacterium urealyticum		
Enterobacter aerogenes		
Enterococcus faecium		
Escherichia coli		
Gardnerella vaginalis		
HPV 16		
HPV 18		
HSV1		
HSV2		
Haemophilus ducreyi		
Morganella morganii		
Mycoplasma genitalium and Mycoplasma Hominis		
Neisseria gonorrhoeae		
Prevotella bivia		
Proteus mirabilis		
Proteus vulgaris		
Providencia stuartii		
Pseudomonas aeruginosa		
Serratia marcescens		
Staphylococcus aureus		
Staphylococcus epidermidis		

NEGATIVE RESISTANCE GENES	ANTIBIOTIC CLASS
aac6-1b/aacA4, ant(3), aph(A6), aac6-1b-cr	Aminoglycosides
SULL, DFRA	Bactrim
CTX-M, PER-1, PER-2, VEB, blaNDM-1, OXA-1, GES	Beta-lactams
OXA-23, OXA-40, OXA-58, OXA-72, IMP-16, NDM, blaOXA-48, OXA-48, KPC, VIM, IMP-7	Carbapenems
ermC, ermA	Macrolides
mecA	Methicillin
mcr-1	Polymyxins
qnrS_Pa04646145_s1, Gyrase A D87N_GTT, Gyrase A S83L_TGG, QnrA	Quinolones
VanB, VanA1, VanA2	Vancomycin

Trichomonas vaginalis Ureaplasma urealyticum

Staphylococcus saprophyticus Treponema pallidum (Syphilis)